Damora Therapeutics (DMRA) financial statements
Net income was -$210M.
The diluted share count rose 13008% over the period (dilution).
Income statement
Fiscal years, from Damora Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Research and development | $20M | $25M | $38M | $48M | $24M | $6M | $27M |
| Selling, general and admin | $2M | $9M | $14M | $13M | $13M | $10M | $10M |
| Operating income | $39M | -$34M | -$52M | -$61M | -$40M | -$22M | -$211M |
| Pre-tax income | -$37M | -$35M | -$52M | -$62M | -$38M | -$21M | -$210M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $41,000 | $50,000 |
| Net income | -$37M | -$35M | -$52M | -$62M | -$38M | -$21M | -$210M |
| EPS (diluted) | -$4,045.50 | -$190.50 | -$51.25 | -$60.75 | -$36.08 | -$18.53 | $3.98 |
| Diluted shares | 0M | 0M | 1M | 1M | 1M | 1M | 1M |
Balance sheet
Fiscal years, from Damora Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $11M | $164M | $100M | $60M | $33M | $14M | $258M |
| Total current assets | $56M | $169M | $110M | $64M | $37M | $17M | $260M |
| Property, plant and equipment | — | — | $203,000 | $357,000 | $78,000 | $57,000 | $36,000 |
| Total assets | $57M | $172M | $122M | $73M | $38M | $17M | $261M |
| Total current liabilities | $8M | $6M | $5M | $11M | $6M | $1M | $20M |
| Total liabilities | $8M | $6M | $5M | $11M | $6M | $1M | $20M |
| Shareholders' equity | -$71M | $165M | $117M | $62M | $32M | $16M | $240M |
| Net debt | -$11M | -$164M | -$63M | -$33M | -$21M | -$14M | -$258M |
Cash flow
Fiscal years, from Damora Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19M | -$38M | -$52M | -$43M | -$37M | -$19M | -$7M |
| Capital spending | — | — | $223,000 | $196,000 | — | — | — |
| Free cash flow | — | — | -$53M | -$43M | — | — | — |
| Stock-based compensation | — | $982,000 | $4M | $6M | $5M | $3M | $998,000 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DMRA.
Open DMRA in InvestinglyFrom Damora Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.